Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adrian Lim

Showing results (71-80 of 120) with videos related to

Pageof 12
Sort By:
Molecular Pharmaceutics|January 17, 2024
Overcoming Resistance in Prostate Cancer Therapy Using a DZ-Simvastatin ConjugateYan Ou, Gina Chia-Yi Chu, Ji Lyu, et al.
European Journal of Cancer (Oxford, England : 1990)|June 11, 2021
Response to letter entitled: Re: Can we replace adjuvant chemotherapy with surveillance for stage IA-C immature ovarian teratomas of any grade? An international multicenter analysisAlice Bergamini, Naveed Sarwar, Gabriella Ferrandina, et al.
Drug and Chemical Toxicology|October 17, 2024
Unraveling the hepatoprotective and anti-pancreatic cancer potential of <i>Caralluma europaea</i>: a comprehensive <i>in vivo, in vitro</i> and in silico evidenceFatima Ez-Zahra Amrati, Adrian Lim, Meryem Slighoua, et al.
European Journal of Cancer (Oxford, England : 1990)|August 9, 2020
Can we replace adjuvant chemotherapy with surveillance for stage IA-C immature ovarian teratomas of any grade? an international multicenter analysisAlice Bergamini, Naveed Sarwar, Gabriella Ferrandina, et al.
Journal of Translational Internal Medicine|March 2, 2023
Focal Liver Lesions other than Hepatocellular Carcinoma in Cirrhosis: Diagnostic ChallengesKathleen Möller, Ehsan Safai Zadeh, Christian Görg, et al.
Clinical Breast Cancer|June 14, 2011
Human epidermal growth factor receptor 2-positive breast cancer relapsing post-adjuvant trastuzumab: pattern of recurrence, treatment and outcomeJonathan Krell, Colin R James, Deep Shah, et al.
Medical Ultrasonography|June 27, 2023
Comments and illustrations of the WFUMB CEUS liver guidelines: Rare vascular pathology, part IIKathleen Moller, Ehsan Safai Zadeh, Christian Görg, et al.
Medical Ultrasonography|August 10, 2024
Comments and illustrations of the WFUMB CEUS liver guidelines: rare benign hematological focal liver lesions (hepatic extramedullary hematopoiesis, Hemophagocytic lymphohistiocytosis, reactive lymphoid hyperplasia)Amjad Alhyari, Ehsan Safai Zadeh, Ana Martín Algíbez, et al.
Breast Cancer Research and Treatment|October 27, 2017
Correction to: IRIS study: a phase II study of the steroid sulfatase inhibitor Irosustat when added to an aromatase inhibitor in ER-positive breast cancer patientsCarlo Palmieri, Rob C Stein, Xinxue Liu, et al.
Breast Cancer Research and Treatment|June 15, 2017
IRIS study: a phase II study of the steroid sulfatase inhibitor Irosustat when added to an aromatase inhibitor in ER-positive breast cancer patientsCarlo Palmieri, Rob C Stein, Xinxue Liu, et al.
Pageof 12

Showing results (71-80 of 120) with videos related to

Sort By:
Pageof 12
Molecular Pharmaceutics|January 17, 2024
Overcoming Resistance in Prostate Cancer Therapy Using a DZ-Simvastatin ConjugateYan Ou, Gina Chia-Yi Chu, Ji Lyu, et al.
European Journal of Cancer (Oxford, England : 1990)|June 11, 2021
Response to letter entitled: Re: Can we replace adjuvant chemotherapy with surveillance for stage IA-C immature ovarian teratomas of any grade? An international multicenter analysisAlice Bergamini, Naveed Sarwar, Gabriella Ferrandina, et al.
Drug and Chemical Toxicology|October 17, 2024
Unraveling the hepatoprotective and anti-pancreatic cancer potential of <i>Caralluma europaea</i>: a comprehensive <i>in vivo, in vitro</i> and in silico evidenceFatima Ez-Zahra Amrati, Adrian Lim, Meryem Slighoua, et al.
European Journal of Cancer (Oxford, England : 1990)|August 9, 2020
Can we replace adjuvant chemotherapy with surveillance for stage IA-C immature ovarian teratomas of any grade? an international multicenter analysisAlice Bergamini, Naveed Sarwar, Gabriella Ferrandina, et al.
Journal of Translational Internal Medicine|March 2, 2023
Focal Liver Lesions other than Hepatocellular Carcinoma in Cirrhosis: Diagnostic ChallengesKathleen Möller, Ehsan Safai Zadeh, Christian Görg, et al.
Clinical Breast Cancer|June 14, 2011
Human epidermal growth factor receptor 2-positive breast cancer relapsing post-adjuvant trastuzumab: pattern of recurrence, treatment and outcomeJonathan Krell, Colin R James, Deep Shah, et al.
Medical Ultrasonography|June 27, 2023
Comments and illustrations of the WFUMB CEUS liver guidelines: Rare vascular pathology, part IIKathleen Moller, Ehsan Safai Zadeh, Christian Görg, et al.
Medical Ultrasonography|August 10, 2024
Comments and illustrations of the WFUMB CEUS liver guidelines: rare benign hematological focal liver lesions (hepatic extramedullary hematopoiesis, Hemophagocytic lymphohistiocytosis, reactive lymphoid hyperplasia)Amjad Alhyari, Ehsan Safai Zadeh, Ana Martín Algíbez, et al.
Breast Cancer Research and Treatment|October 27, 2017
Correction to: IRIS study: a phase II study of the steroid sulfatase inhibitor Irosustat when added to an aromatase inhibitor in ER-positive breast cancer patientsCarlo Palmieri, Rob C Stein, Xinxue Liu, et al.
Breast Cancer Research and Treatment|June 15, 2017
IRIS study: a phase II study of the steroid sulfatase inhibitor Irosustat when added to an aromatase inhibitor in ER-positive breast cancer patientsCarlo Palmieri, Rob C Stein, Xinxue Liu, et al.
Pageof 12